fbpx
Size of letters 1x
Site color
Image
Additionally
Line height
Letter spacing
Font
Embedded items (videos, maps, etc.)
 

Sayenko Kharenko advised Viseven on attracting investment from Horizon Capital

18/ 01/ 2024
  Sayenko Kharenko has acted as a legal counsel to Viseven, a global MarTech company servicing pharmaceutical and life sciences industries, on attracting investment from Horizon Capital, a leading private equity firm.  Sayenko Kharenko provided full-scope legal support to Viseven, including drafting and negotiating the transaction documentation and assistance during completion.  “We were delighted with the top-notch legal work from Sayenko Kharenko during every stage of the deal. Their team knew their field inside and out and was consistently result-oriented, guiding us smoothly through all intricacies of the transaction, so that Viseven team could focus on getting the most value from the transaction.” – comments Nataliya Andriychuk, the CEO of Viseven.   Partner Alina Plyushch comments: “We were pleased to advise Viseven on this significant investment deal. This transaction exemplifies the potential of Ukrainian tech companies to achieve global success”.  Founded in 2009, Viseven has expanded to over 30 countries, with development hubs in Ukraine, Argentina, Estonia, India, Poland, and North America. Known as an innovator, the Company has been constantly launching new products, including a digital content factory, cloud-based CRM and CLM suites powered by no-code functionality and enabled by AI tools, for an end-to-end digital marketing platform. Led by Nataliya Andreychuk (CEO) and co-founders Vyacheslav Vasylenko (COO) and Roman Vasylenko (CTO), Viseven services over 50 pharma and life sciences customers, and many top-20 global companies, including Abbott, AbbVie, Amgen, Bayer, Biogen, Ipsen, Lilly, Novo Nordisk, Servier Laboratories, and others. The Company counts AVentures Capital and Horizon Capital among its investors and remains founders` led.   Horizon Capital is the leading private equity firm in Central and Eastern Europe, managing over $1.5 billion in assets. This investment marks Horizon Capital’s other investment from its latest fund, Horizon Capital Growth Fund IV, investing in fast-growing companies in Ukraine.  Sayenko Kharenko team advising Viseven was led by partner Alina Plyushch and senior associates Dmitriy Riabikin and Roman Drozhanskyi with support from associate Zarina Khalimon and junior associate Dmytro Zaiachkivskyi. 

Sayenko Kharenko has acted as a legal counsel to Viseven, a global MarTech company servicing pharmaceutical and life sciences industries, on attracting investment from Horizon Capital, a leading private equity firm. 

Sayenko Kharenko provided full-scope legal support to Viseven, including drafting and negotiating the transaction documentation and assistance during completion. 

“We were delighted with the top-notch legal work from Sayenko Kharenko during every stage of the deal. Their team knew their field inside and out and was consistently result-oriented, guiding us smoothly through all intricacies of the transaction, so that Viseven team could focus on getting the most value from the transaction.” – comments Nataliya Andriychuk, the CEO of Viseven.  

Partner Alina Plyushch comments: “We were pleased to advise Viseven on this significant investment deal. This transaction exemplifies the potential of Ukrainian tech companies to achieve global success”. 

Founded in 2009, Viseven has expanded to over 30 countries, with development hubs in Ukraine, Argentina, Estonia, India, Poland, and North America. Known as an innovator, the Company has been constantly launching new products, including a digital content factory, cloud-based CRM and CLM suites powered by no-code functionality and enabled by AI tools, for an end-to-end digital marketing platform. Led by Nataliya Andreychuk (CEO) and co-founders Vyacheslav Vasylenko (COO) and Roman Vasylenko (CTO), Viseven services over 50 pharma and life sciences customers, and many top-20 global companies, including Abbott, AbbVie, Amgen, Bayer, Biogen, Ipsen, Lilly, Novo Nordisk, Servier Laboratories, and others. The Company counts AVentures Capital and Horizon Capital among its investors and remains founders` led.  

Horizon Capital is the leading private equity firm in Central and Eastern Europe, managing over $1.5 billion in assets. This investment marks Horizon Capital’s other investment from its latest fund, Horizon Capital Growth Fund IV, investing in fast-growing companies in Ukraine. 

Sayenko Kharenko team advising Viseven was led by partner Alina Plyushch and senior associates Dmitriy Riabikin and Roman Drozhanskyi with support from associate Zarina Khalimon and junior associate Dmytro Zaiachkivskyi

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Start
in the Telegram bot
Read articles. Share in social networks

Spelling error report

The following text will be sent to our editors: